MX347829B - Molécula fv de unión a antígeno multivalente. - Google Patents
Molécula fv de unión a antígeno multivalente.Info
- Publication number
- MX347829B MX347829B MX2014000816A MX2014000816A MX347829B MX 347829 B MX347829 B MX 347829B MX 2014000816 A MX2014000816 A MX 2014000816A MX 2014000816 A MX2014000816 A MX 2014000816A MX 347829 B MX347829 B MX 347829B
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- binding molecule
- binding
- polypeptide
- molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un aspecto, la presente invención se relaciona con una molécula de unión de antígeno específica para albúmina y CD3 que comprende dos cadenas polipeptidicas, teniendo cada cadena polipeptídica al menos cuatro dominios variables en una orientación que evita la formación de Fv y las dos cadenas polipeptídicas se dimerizan con otra formando por lo tanto una molécula de unión de antígeno multivalente. Sobre cada una de las dos cadenas polipeptídicas los cuatro dominios variables están arreglados en el orden VLA-VHB-VLB-VHA del N-terminal al C-terminal del polipéptido. Las composiciones de la molécula de unión de antígeno y los métodos de uso de la molécula de unión de antígeno o las composiciones de la misma para el tratamiento de varias enfermedades también son proporcionadas aquí.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2011/062673 WO2013013700A1 (en) | 2011-07-22 | 2011-07-22 | Multivalent antigen-binding fv molecule |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014000816A MX2014000816A (es) | 2014-07-09 |
MX347829B true MX347829B (es) | 2017-05-15 |
Family
ID=44719851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014000816A MX347829B (es) | 2011-07-22 | 2011-07-22 | Molécula fv de unión a antígeno multivalente. |
Country Status (8)
Country | Link |
---|---|
JP (1) | JP5938473B2 (es) |
CN (1) | CN103687879B (es) |
AU (1) | AU2011373925B2 (es) |
BR (1) | BR112014001573B8 (es) |
CA (1) | CA2842649C (es) |
MX (1) | MX347829B (es) |
RU (1) | RU2613368C2 (es) |
WO (1) | WO2013013700A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3148580B1 (en) | 2014-05-29 | 2021-01-20 | MacroGenics, Inc. | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
CN106661119A (zh) | 2014-07-01 | 2017-05-10 | 辉瑞公司 | 双特异性异二聚化双抗体及其用途 |
US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
EP3250601A4 (en) | 2015-01-26 | 2018-07-11 | MacroGenics, Inc. | Multivalent molecules comprising dr5-binding domains |
KR102537102B1 (ko) | 2015-05-29 | 2023-05-25 | 엠피베나 테라퓨틱스, 인크. | 이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법 |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
SI3456346T1 (sl) | 2015-07-30 | 2021-11-30 | Macrogenics, Inc. | Molekule za vezavo PD-1 in LAG-3 in postopki za uporabo le-teh |
GEP20217328B (en) | 2015-12-14 | 2021-12-10 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
US20170233472A1 (en) | 2016-02-17 | 2017-08-17 | Macrogenics, Inc. | ROR1-Binding Molecules, and Methods of Use Thereof |
EP3442574A4 (en) | 2016-04-15 | 2019-12-11 | MacroGenics, Inc. | NOVEL B7-H3 BINDING MOLECULES, THEIR ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE |
AR110424A1 (es) | 2016-12-23 | 2019-03-27 | Macrogenics Inc | Moléculas de unión a adam9 y métodos de uso de las mismas |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
AU2018228719B2 (en) * | 2017-02-28 | 2023-03-30 | Affimed Gmbh | Tandem diabody for CD16A-directed NK-cell engagement |
KR20200013230A (ko) * | 2017-06-05 | 2020-02-06 | 누맙 세러퓨틱스 아게 | 적어도 cd3 및 hsa를 표적화하는 헤테로-이량체 다중 특이적 항체 포맷 |
CA3080248A1 (en) | 2017-10-26 | 2019-05-02 | Saint-Gobain Glass France | Add-on part having an integrated camera module |
KR20200098590A (ko) | 2017-12-12 | 2020-08-20 | 마크로제닉스, 인크. | 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도 |
CA3237846A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
US20210238286A1 (en) * | 2018-06-07 | 2021-08-05 | Cullinan Management, Inc. | Multi-specific binding proteins and methods of use thereof |
RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
GB201912681D0 (en) | 2019-09-04 | 2019-10-16 | Eth Zuerich | Bispecific binding agent that binds to cd117/c-kit and cd3 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
DE19819846B4 (de) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
EP1500665B1 (en) * | 2002-04-15 | 2011-06-15 | Chugai Seiyaku Kabushiki Kaisha | METHODS FOR CONSTRUCTING scDb LIBRARIES |
EP1400534B1 (en) | 2002-09-10 | 2015-10-28 | Affimed GmbH | Human CD3-specific antibody with immunosuppressive properties |
JPWO2005056605A1 (ja) * | 2003-12-12 | 2007-12-06 | 中外製薬株式会社 | 3量体以上の受容体を認識する改変抗体 |
EP1870458B1 (en) * | 2005-03-31 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2 STRUCTURAL ISOMERS |
GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
US9315584B2 (en) * | 2009-03-25 | 2016-04-19 | Tohoku University | LH-type bispecific antibody |
ES2582001T3 (es) * | 2010-02-25 | 2016-09-08 | Affimed Gmbh | Molécula que se une a antígeno y usos de la misma |
-
2011
- 2011-07-22 WO PCT/EP2011/062673 patent/WO2013013700A1/en active Application Filing
- 2011-07-22 AU AU2011373925A patent/AU2011373925B2/en not_active Ceased
- 2011-07-22 JP JP2014520541A patent/JP5938473B2/ja not_active Expired - Fee Related
- 2011-07-22 CA CA2842649A patent/CA2842649C/en active Active
- 2011-07-22 CN CN201180072477.5A patent/CN103687879B/zh not_active Expired - Fee Related
- 2011-07-22 MX MX2014000816A patent/MX347829B/es active IP Right Grant
- 2011-07-22 RU RU2013157040A patent/RU2613368C2/ru active
- 2011-07-22 BR BR112014001573A patent/BR112014001573B8/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2013157040A (ru) | 2015-08-27 |
BR112014001573B1 (pt) | 2022-08-30 |
WO2013013700A1 (en) | 2013-01-31 |
BR112014001573A2 (pt) | 2017-02-21 |
RU2613368C2 (ru) | 2017-03-16 |
JP2014527515A (ja) | 2014-10-16 |
AU2011373925A1 (en) | 2014-01-16 |
CA2842649A1 (en) | 2013-01-31 |
CA2842649C (en) | 2020-01-21 |
JP5938473B2 (ja) | 2016-06-22 |
AU2011373925B2 (en) | 2016-04-28 |
BR112014001573B8 (pt) | 2022-11-08 |
MX2014000816A (es) | 2014-07-09 |
CN103687879A (zh) | 2014-03-26 |
CN103687879B (zh) | 2016-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX347829B (es) | Molécula fv de unión a antígeno multivalente. | |
EP2371866A3 (en) | Multivalent antigen-binding Fv molecule | |
HRP20211343T1 (hr) | Protutijela protiv dkk-1 | |
AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
NZ761188A (en) | Antibody molecules to tim-3 and uses thereof | |
MX2021007006A (es) | Anticuerpo anti-calicreina-2 humanizado. | |
MY191428A (en) | Antigen binding molecules comprising a tnf family ligand trimer | |
MX353931B (es) | Anticuerpos que se unen a ox40 y sus usos. | |
WO2015173756A3 (en) | Bispecific antibodies with engineered ch1-cl interfaces | |
NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
NZ626269A (en) | Anti-phf-tau antibodies and their uses | |
WO2015138600A3 (en) | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies | |
TN2014000134A1 (en) | Therapeutic peptides | |
MX366223B (es) | Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2. | |
MX2022013667A (es) | Construcciones polipeptidicas de union al antigeno que comprenden cadenas ligeras kappa y lambda y usos de estas. | |
EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
MX2018009498A (es) | Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1. | |
MX2014008102A (es) | Inmunoglobulinas de dominio variable dual contra receptores. | |
NZ616761A (en) | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same | |
TN2014000120A1 (en) | Cd27l antigen binding proteins | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
MX2014015043A (es) | Anticuerpos anti-trka humanizados con sustituciones de aminoacidos. | |
GB201005064D0 (en) | Biological products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |